Dyne Therapeutics director granted stock options

Dyne Therapeutics, Inc. director Edward Hurwitz received a grant of stock options as part of his compensation.

Rhea-AI Filing Summary

Dyne Therapeutics, Inc. director Edward Hurwitz received a grant of stock options as part of his compensation. The award covers 35,152 stock options, each exercisable for one share of common stock at an exercise price of $17.04 per share. According to the disclosure, these options were granted on June 5, 2026 and will vest in full on the earlier of June 5, 2027 or the company’s 2027 Annual Meeting of Stockholders, provided he continues in service. Following this grant, Hurwitz holds 35,152 derivative securities from this award.

Insider Trade Summary

Grant/Award: 35,152 shares

Grant/Award 1 txn

Insider HURWITZ EDWARD

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock option (right to buy)	35,152	$0.00	$0.00

Holdings After Transaction: Stock option (right to buy) — 35,152 contracts (Direct)

Footnotes (1)

1. F1. This option was granted on June 5, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 5, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.

Key Figures

Options granted: 35,152 options Exercise price: $17.04 per share Shares underlying options: 35,152 shares +2 more

5 metrics

Options granted 35,152 options Stock option grant to director on June 5, 2026

Exercise price $17.04 per share Conversion or exercise price for the option award

Shares underlying options 35,152 shares Common stock underlying the granted options

Expiration date June 4, 2036 Option award expiration

Shares following transaction 35,152 derivative securities Total options held from this award after grant

Key Terms

Stock option (right to buy), exercise price, vest in full, Annual Meeting of Stockholders, +1 more

5 terms

Stock option (right to buy) financial

"security_title: Stock option (right to buy)"

exercise price financial

"conversion_or_exercise_price: 17.0400"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

vest in full financial

"scheduled to vest in full on the earlier of"

Annual Meeting of Stockholders regulatory

"the Issuer's 2027 Annual Meeting of Stockholders"

Grant, award, or other acquisition financial

"transaction_code_description: Grant, award, or other acquisition"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Dyne Therapeutics (DYN) report for Edward Hurwitz?

Dyne Therapeutics reported that director Edward Hurwitz received a grant of 35,152 stock options. These options give him the right to buy Dyne common stock at a fixed exercise price as part of his equity-based compensation package.

How many stock options were granted to the Dyne Therapeutics (DYN) director?

The director was granted 35,152 stock options. Each option represents the right to purchase one share of Dyne Therapeutics common stock, subject to vesting conditions and payment of the stated exercise price when exercised.

What is the exercise price of the new Dyne Therapeutics (DYN) stock options?

The newly granted options have an exercise price of $17.04 per share. This is the price the director must pay per share if he chooses to exercise the options after they vest and before they expire.

When do the Dyne Therapeutics (DYN) options granted to Edward Hurwitz vest?

The options are scheduled to vest in full on the earlier of June 5, 2027 or the date of Dyne’s 2027 Annual Meeting of Stockholders. Vesting is conditioned on his continued service with the company.

What is the expiration date of the Dyne Therapeutics (DYN) director’s stock options?

The reported expiration date for this option grant is June 4, 2036. After that date, any unexercised options from this award will lapse and can no longer be used to purchase Dyne Therapeutics common stock.

Does the Form 4 show an open-market buy or sell for Dyne Therapeutics (DYN)?

No open-market buy or sell is reported. The Form 4 shows a grant of stock options coded as an acquisition (transaction code A), reflecting equity compensation rather than a market purchase or sale of existing Dyne shares.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/09/2026 - 05:15 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

HURWITZ EDWARD

(Last) (First) (Middle)

C/O DYNE THERAPEUTICS, INC.

1560 TRAPELO ROAD

(Street)

WALTHAM MASSACHUSETTS 02451

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Dyne Therapeutics, Inc. [ DYN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
06/05/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock option (right to buy)	$17.04	06/05/2026		A		35,152		(1)	06/04/2036	Common Stock	35,152	$0.00	35,152	D

Explanation of Responses:

1. This option was granted on June 5, 2026. The shares underlying the option are scheduled to vest in full on the earlier of (i) June 5, 2027 or (ii) the date of the Issuer's 2027 Annual Meeting of Stockholders, subject to continued service.

	/s/ Ron Caponigro, Attorney-in-Fact	06/09/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)